IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11590128 B1

PDFFull Text
Date of Patent:
Feb. 28, 2023

Filed:

Jun. 07, 2022

Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor

Applicants:

Genentech, Inc., South San Francisco, CA (US);

Hoffmann-la Roche Inc., Little Falls, NJ (US);

Abbvie Inc., North Chicago, IL (US);

Inventors:

Deepak Sampath, South San Francisco, CA (US);

Christian Klein, Iffeldorf, DE;

Wayne John Fairbrother, South San Francisco, CA (US);

Sari L. Heitner Enschede, River Forest, IL (US);

Rod A. Humerickhouse, Highland Park, IL (US);

Andrew W. Roberts, Melbourne, AU;

John F. Seymour, Melbourne, AU;

Assignees:

GENENTECH, INC., South San Francisco, CA (US);

HOFFMANN-LA ROCHE INC., Little Falls, NJ (US);

ABBVIE INC., North Chicago, IL (US);

Attorney:

Jones Day

Primary Examiner:

Yan Xiao

Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/02 (2006.01); A61K 31/04 (2006.01); A61K 31/10 (2006.01); A61K 31/18 (2006.01); A61K 31/33 (2006.01); A61K 31/436 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/45 (2006.01); A61K 31/505 (2006.01); A61K 31/63 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/02 (2013.01); A61K 31/04 (2013.01); A61K 31/10 (2013.01); A61K 31/18 (2013.01); A61K 31/33 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/45 (2013.01); A61K 31/505 (2013.01); A61K 31/63 (2013.01); A61K 39/39558 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01);
Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Find Patent Forward Citations

Loading…